- Home
- CCSI vs AVTX Comparison
CCSI vs AVTX Comparison
Compare CCSI & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCSI | AVTX |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 648.0M | 710.1M |
| IPO Year | 2022 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CCSI | AVTX |
|---|---|---|
| Price | $37.39 | $6.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $42.25 | ★ $44.08 |
| AVG Volume (30 Days) | 84.7K | ★ 2.1M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ 2.72 | N/A |
| Revenue | ★ $349,696,000.00 | $27,813,137.00 |
| Revenue This Year | $3.01 | N/A |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | $13.58 | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $20.20 | $6.85 |
| 52 Week High | $41.40 | $24.27 |
Technical Indicators
Market Signals| Indicator | CCSI | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.95 | 17.33 |
| Support Level | $32.99 | N/A |
| Resistance Level | $38.38 | $20.54 |
| Average True Range (ATR) | 1.21 | 0.99 |
| MACD | 0.13 | -0.43 |
| Stochastic Oscillator | 85.71 | 5.34 |
Price Performance
Historical ComparisonAbout CCSI Consensus Cloud Solutions Inc.
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in the fax cloud business. The company's offerings include communication, data extraction, and digital signature solutions that enable users to securely access, exchange, and manage information across organizational and geographic boundaries. It serves multiple industry verticals, including healthcare, government, financial services, legal, and education. Geographically, the company operates in the United States, Canada, Ireland, and other countries. It derives the maximum revenue from the United States.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.